European Regulatory Affairs: In-depth review of current registration procedures in the European Union

This training course will provide an excellent introduction to the European Regulatory procedures for personnel in regulatory affairs, clinical research, project management and other disciplines involved in the development of medicinal products

The course will cover the evolution of the registration systems available for approval of products since January 1995 in the European Union, together with major changes in New Medicines Legislation. Title IV of Regulation EC726/2004 on the European Medicines Agency - Responsibilities and Administrative Structure, came into effect on May 20, 2004. The remainder of the Regulation and all of Directive 2004/27/EC became effective in November 20, 2005.

The very important changes in New Medicine Legislation concerning regulatory procedures, access to Centralised and Mutual Recognition Procedures, reduction in Regulatory Data protection will be described in detail.

Detailed review will be offered on the changed Centralised and Mutual Recognition Procedures and New Decentralised Procedure with discussion of practical examples of product types suitable for each procedure.

Other issues that impact on successful regulatory strategy in Europe, Harmonisation of Summary of Product Characteristics, Article 30 and Article 31 referrals and Supplementary Protection Certificate for Patents will be described.

Also reviewed and discussed is the legal status of medicinal products and the procedure for switching from prescription only sale to OTC sale, legislation controlling medical devices and the Clinical Trial Directive.

This course will provide strategic advice on how to file applications for the marketing authorisations in the European Union for staff involved in regulatory affairs.
Regulatory strategy which impacts on commercial, business and licensing arrangements will be of importance to those responsible for business development.

Key Topics

• European Union
• Centralised Procedure
• Decentralised Procedure
• Mutual Recognition Procedure
• National Procedure
• Key issues to consider for business opportunities
• Regulatory strategy
• Legal status of products and switching from Rx to OTC
• Medical devices legislation 
• Clinical Trial Directive

Professionals in regulatory affairs, clinical research, project management, toxicology, product development and data management.

Cancellation Policy

Cancellations must be made in writing and be received at the DIA Europe office five working days prior to the course start date.
                                                                                        
Cancellations are subject to an administrative fee:
Full Meeting Cancellation:

Industry (Member/Non-member) = € 200.00
Government/Academia/Non-profit (Member/Non-member) = € 100.00

Registrants who do not cancel five working days prior to the course start date and do not attend, will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled DIA Europe is not responsible for airfare, hotel or other costs incurred by registrants. Registrants are responsible for cancelling their own hotel and travel reservations.

Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute registrants will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

At the conclusion of this course, participants should be able to:

• Explain the registration procedures for filing applications for medicinal products in the European Union and recognise which routes are available for each product type (NCE, biotechnology, OTC and generic)
• Describe the concepts of global marketing authorisation and regulatory data protection
• Discuss the key issues that impact the choice of the registration procedure including trademarks and patents
• Describe the legislation effecting medical devices and procedures for obtaining Clinical Trial and Ethics Committee approval in Europe